Mereo BioPharma Group (MREO) Stock Forecast, Price Target & Predictions
MREO Stock Forecast
Mereo BioPharma Group stock forecast is as follows: an average price target of $6.75 (represents a 57.71% upside from MREO’s last price of $4.28) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
MREO Price Target
The average price target for Mereo BioPharma Group (MREO) is $6.75 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $4.00. This represents a potential 57.71% upside from MREO's last price of $4.28.
MREO Analyst Ratings
According to 2 Wall Street analysts, Mereo BioPharma Group's rating consensus is 'Buy'. The analyst rating breakdown for MREO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Mereo BioPharma Group Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 20, 2024 | Joseph Schwartz | Leerink Partners | $8.00 | $3.98 | 101.01% | 86.92% |
| Jun 12, 2024 | Jack Allen | Robert W. Baird | $8.00 | $3.83 | 108.88% | 86.92% |
| Jun 12, 2024 | Gil Blum | Needham | $7.00 | $3.52 | 98.86% | 63.55% |
| Mar 28, 2024 | Gil Blum | Needham | $6.00 | $3.00 | 100.00% | 40.19% |
| Aug 12, 2022 | - | Cantor Fitzgerald | $4.00 | $1.35 | 196.30% | -6.54% |
The latest Mereo BioPharma Group stock forecast, released on Jun 20, 2024 by Joseph Schwartz from Leerink Partners, set a price target of $8.00, which represents a 101.01% increase from the stock price at the time of the forecast ($3.98), and a 86.92% increase from MREO last price ($4.28).
Mereo BioPharma Group Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $8.00 | $7.25 |
| Last Closing Price | $4.28 | $4.28 | $4.28 |
| Upside/Downside | -100.00% | 86.92% | 69.39% |
In the current month, the average price target of Mereo BioPharma Group stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Mereo BioPharma Group's last price of $4.28. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 12, 2024 | Needham | Buy | Buy | Hold |
| Mar 28, 2024 | Needham | Buy | Buy | Hold |
| Aug 12, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
| Jun 06, 2022 | Needham | Buy | Buy | Hold |
| Mar 17, 2022 | Needham | Buy | Buy | Hold |
| Apr 05, 2021 | Needham | - | Buy | Initialise |
Mereo BioPharma Group's last stock rating was published by Needham on Jun 12, 2024. The company gave MREO a "Buy" rating, the same as its previous rate.
Mereo BioPharma Group Financial Forecast
Mereo BioPharma Group Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | $14.78M | $11.04M | $28.57M | - | $19.75M | $3.27M |
| High Forecast | - | - | $14.78M | $11.04M | $28.57M | - | $19.75M | $3.27M |
| Low Forecast | - | - | $14.78M | $11.04M | $28.57M | - | $19.75M | $3.27M |
| # Analysts | 3 | 3 | 3 | 3 | 5 | 4 | 4 | 3 |
| Surprise % | - | - | - | - | - | - | - | - |
Mereo BioPharma Group's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. MREO's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Mereo BioPharma Group EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 5 | 4 | 4 | 3 |
| EBITDA | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | $-7.56M | $-5.64M | $-14.61M | - | $-10.10M | $-1.67M |
| High Forecast | - | - | $-7.56M | $-5.64M | $-14.61M | - | $-10.10M | $-1.67M |
| Low Forecast | - | - | $-7.56M | $-5.64M | $-14.61M | - | $-10.10M | $-1.67M |
| Surprise % | - | - | - | - | - | - | - | - |
undefined analysts predict MREO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Mereo BioPharma Group's previous annual EBITDA (undefined) of $NaN.
Mereo BioPharma Group Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 5 | 4 | 4 | 3 |
| Net Income | - | - | - | - | - | - | - | - |
| Avg Forecast | $-1.80M | $-1.80M | $-448.82K | $-673.24K | $673.24K | $-2.02M | $-1.12M | $-58.24M |
| High Forecast | $-1.80M | $-1.80M | $-448.82K | $-673.24K | $673.24K | $-1.01M | $-1.12M | $-58.24M |
| Low Forecast | $-1.80M | $-1.80M | $-448.82K | $-673.24K | $673.24K | $-2.02M | $-1.12M | $-58.24M |
| Surprise % | - | - | - | - | - | - | - | - |
Mereo BioPharma Group's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MREO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Mereo BioPharma Group SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 5 | 4 | 4 | 3 |
| SG&A | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | $-180.76M | $-134.97M | $-349.47M | - | $-241.56M | $-40.03M |
| High Forecast | - | - | $-180.76M | $-134.97M | $-349.47M | - | $-241.56M | $-40.03M |
| Low Forecast | - | - | $-180.76M | $-134.97M | $-349.47M | - | $-241.56M | $-40.03M |
| Surprise % | - | - | - | - | - | - | - | - |
Mereo BioPharma Group's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to MREO last annual SG&A of $NaN (undefined).
Mereo BioPharma Group EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 5 | 4 | 4 | 3 |
| EPS | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.01 | $-0.01 | $-0.00 | $-0.00 | - | $-0.01 | $-0.01 | $-0.41 |
| High Forecast | $-0.01 | $-0.01 | $-0.00 | $-0.00 | - | $-0.01 | $-0.01 | $-0.41 |
| Low Forecast | $-0.01 | $-0.01 | $-0.00 | $-0.00 | - | $-0.01 | $-0.01 | $-0.41 |
| Surprise % | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Mereo BioPharma Group's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MREO previous annual EPS of $NaN (undefined).
Mereo BioPharma Group Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.05 | $5.50 | 10900.00% | Buy |
| HEPA | Hepion Pharmaceuticals | $0.74 | $70.00 | 9359.46% | Buy |
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
MREO Forecast FAQ
Is Mereo BioPharma Group a good buy?
Yes, according to 2 Wall Street analysts, Mereo BioPharma Group (MREO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of MREO's total ratings.
What is MREO's price target?
Mereo BioPharma Group (MREO) average price target is $6.75 with a range of $4 to $8, implying a 57.71% from its last price of $4.28. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Mereo BioPharma Group stock go up soon?
According to Wall Street analysts' prediction for MREO stock, the company can go up by 57.71% (from the last price of $4.28 to the average price target of $6.75), up by 86.92% based on the highest stock price target, and down by -6.54% based on the lowest stock price target.
Can Mereo BioPharma Group stock reach $6?
MREO's average twelve months analyst stock price target of $6.75 supports the claim that Mereo BioPharma Group can reach $6 in the near future.
What are Mereo BioPharma Group's analysts' financial forecasts?
Mereo BioPharma Group's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $48.32M (high $48.32M, low $48.32M), average EBITDA is $-24.713M (high $-24.713M, low $-24.713M), average net income is $-2.476M (high $-1.464M, low $-2.476M), average SG&A $-591M (high $-591M, low $-591M), and average EPS is $-0.0174 (high $-0.0103, low $-0.0174). MREO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $25.81M (high $25.81M, low $25.81M), average EBITDA is $-13.202M (high $-13.202M, low $-13.202M), average net income is $-4.713M (high $-4.713M, low $-4.713M), average SG&A $-316M (high $-316M, low $-316M), and average EPS is $-0.0331 (high $-0.0331, low $-0.0331).